Following this transaction Farrington Thomas’ holding in the company was increased by 18.1% to a total of $669.3K. In addition to Farrington Thomas, 10 other PRGO executives reported Buy trades in the last month.
The company has a one-year high of $58.83 and a one-year low of $38.20. PRGO’s market cap is $5.45 billion and the company has a P/E ratio of -34.20.
Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $52.00, reflecting a -20.7% downside.
The insider sentiment on Perrigo Company has been positive according to 52 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Perrigo Co. Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals. The Consumer Healthcare Americas segment comprises the U.S., Mexico and Canada consumer healthcare business. The Consumer Healthcare International segment includes branded consumer healthcare business primarily in Europe and consumer focused businesses in the U.K., Australia, and Israel. The Prescription Pharmaceuticals refers to the U.S. prescription pharmaceuticals business. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.